• Engage a patient population that mirrors the epidemiology of the disease studied
• Assure the ecosystem around the trials reflects diverse populations being served. Includes research sites, principal investigators, and extended care teams
• Design in inclusivity from start
• Black Americans represent 13% of the US population but reflect only about 4% of participants in clinical trials
• Hispanics represent 16% of the US population but only about 3% of clinical trial participants
• In general 80% of patients taking part in clinical trials are white*
• Better Science. Safety and efficacy of new medicines should be assessed in the patients with the condition
• Personalized Medicine. Understanding the range of different responses to treatments based on genetic variations
• Data. Better inform treatment decisions by making new options available to patients
• Address disparity and inequity
(1)*CDC Heart Disease Facts https://www.cdc.gov/heartdisease/facts.htm
(2)Cancer Facts & Figures 2020 https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
(3)The Burden of Cancer in Asian Americans: A Report of National Mortality Trends by Asian Ethnicity http://cebp.aacrjournals.org/content/25/10/1371